Vitamin Therapy Cost-Effective In Treating Macular Degeneration – Study
This article was originally published in The Tan Sheet
Vitamin therapy is a cost-effective approach to lowering the risk of visual impairment in patients diagnosed with age-related macular degeneration, according to a study recently published in the American Academy of Ophthalmology
You may also be interested in...
Nearly 100 centers working on an NIH study on the effects of antioxidants and fish oil on progression of age-related macular degeneration seek 4,000 people ages 50 to 85 with AMD to participate, according to an Oct. 12 announcement. The National Eye Institute, which says nearly 2 mil. people in the U.S. suffer from vision loss due to advanced AMD and 7 mil. with AMD are at "substantial risk," expects the Age-Related Eye Disease Study 2 (AREDS2) to build upon results from the first AREDS data released in 2001 (1"The Tan Sheet" Oct. 15, 2001, p. 3). Those results showed high-dose antioxidant vitamins and minerals (vitamins C and E, beta-carotene, zinc, and copper) reduced the risk of progression to advanced AMD by 25%, and the risk of moderate vision loss by 19%. Results of a separate study published this year showed higher intake of omega-3 fatty acids could have prevented an estimated 22% of the cases of AMD (2"The Tan Sheet" July 17, 2006, p 9). DSM will supply the supplements for AREDS2...
CNR’s Online Wellness Library gets a new design for easier navigation; AHPA requests revisions to FDA’s food recordkeeping directive; and NPA touts legislative win in Illinois.
RBC Life Sciences may face regulatory scrutiny after ignoring BBB National Programs' questions about sales representatives’ COVID-19 claims and for potential income and its unauthorized use of accreditation logos.